Bottom line
DUSL vs LABU: the short answer
DUSL (Direxion Daily Industrials Bull 3X ETF) and LABU (Direxion Daily S&P Biotech Bull 3X ETF) are both etfs.
LABU is cheaper at 0.96% vs 0.97% — a difference of $1.00 a year per $10,000 invested.
Over five years, DUSL returned +22.8% a year vs −39.6% for LABU.
Updated Nov 19, 2026
DUSL vs LABU side by side
| DUSL | LABU | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Direxion | Direxion |
| Category | Leveraged & Inverse | Leveraged & Inverse |
| Expense ratio | 0.97% | 0.96% |
| Annual cost per $10k | $97 | $96 |
| 10-yr cost on $10k (prospectus) | $1,200 | $1,178 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +36.8% | +78.7% |
| 5-yr return (annualized) | +22.8% | −39.6% |
| 10-yr return (annualized) | — | −20.8% |
| Best quarter | +59.2% | +161.5% |
| Worst quarter | −72.0% | −67.4% |
| Net assets (fund) | $56.5M | $494.4M |
| Number of holdings | 90 | 163 |
| Portfolio turnover | 44% | 107% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | DUSL | LABU | Difference |
|---|---|---|---|
| 2025 | +36.8% | +78.7% | −41.9% |
| 2024 | +34.8% | −25.9% | +60.8% |
| 2023 | +36.8% | −13.4% | +50.2% |
| 2022 | −31.0% | −80.3% | +49.3% |
| 2021 | +60.8% | −64.3% | +125.1% |
| 2020 | −20.2% | +74.7% | −94.9% |
| 2019 | +87.7% | +74.6% | +13.1% |
| 2018 | −44.9% | −57.3% | +12.4% |
Source: Fund prospectus bar charts
Holdings overlap
8 of DUSL's top 25 holdings also appear in LABU's top 25.
| Holding | DUSL | LABU |
|---|---|---|
| Goldman Financial | 18.28% | 14.83% |
| N/a | 5.46% | 3.87% |
| N/a | 4.68% | 3.87% |
| Dreyfus | 4.54% | 15.86% |
| N/a | 3.50% | 3.87% |
| N/a | 2.96% | 3.87% |
| N/a | 2.77% | 3.87% |
| Goldman Sachs Liq Es Fd A | 2.06% | 5.35% |
Source: SEC Form N-PORT
DUSL top 10
- Goldman Financial — 18.28%
- N/a — 5.46%
- General Electric Co — 4.92%
- Caterpillar Inc — 4.91%
- N/a — 4.68%
- Dreyfus — 4.54%
- Rtx Corp — 3.79%
- N/a — 3.50%
- Ge Vernova Inc — 3.48%
- N/a — 2.96%
LABU top 10
- Dreyfus — 15.86%
- Goldman Financial — 14.83%
- N/a — 9.63%
- N/a — 7.30%
- Goldman Sachs Liq Es Fd A — 5.35%
- N/a — 4.85%
- N/a — 3.87%
- Apogee Therapeutics Inc — 1.11%
- Oruka Therapeutics Inc — 1.03%
- Dianthus Therapeutics Inc — 0.96%
FAQ
What is the difference between DUSL and LABU?
Which is cheaper, DUSL or LABU?
Should I own both DUSL and LABU?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.